Drugs for Waldenstroem's Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 305)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 4 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
2 |
|
Lenograstim |
Approved, Investigational |
Phase 4 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
3 |
|
Thiotepa |
Approved, Investigational |
Phase 4 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
Tepadina
Tespa
Tespamin
thio Tepa
Thiophosphamide
|
Thioplex
thio-Tepa
Thiotepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
4 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
5 |
|
Orange |
Approved |
Phase 3 |
|
|
|
6 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
7 |
|
Chlorambucil |
Approved |
Phase 3 |
|
305-03-3 |
2708 |
Synonyms:
23125_FLUKA
305-03-3
4-(Bis(2-chloroethyl)amino)benzenebutanoic acid
4-(P-Bis(b-chloroethyl)aminophenyl)butyrate
4-(P-Bis(b-chloroethyl)aminophenyl)butyric acid
4-(P-Bis(beta-chloroethyl)aminophenyl)butyrate
4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid
4-(P-Bis(beta-chloroethyl)aminophenyl)butyric acid
4-(P-Bis(β-chloroethyl)aminophenyl)butyrate
4-(p-bis(β-chloroethyl)aminophenyl)butyric acid
4-(P-Bis(β-chloroethyl)aminophenyl)butyric acid
4-[P-[Bis(2-chloroethyl)amino]phenyl]butyrate
4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
4-[P-[Bis(2-chloroethyl)amino]phenyl]butyric acid
AB00051938
AC1L1EAB
AC1Q75DO
AI3-26083
Ambochlorin
Amboclorin
BPBio1_001208
BRD-K29458283-001-05-9
BRN 0999011
BSPBio_001098
BSPBio_001971
C 0253
C0253_SIGMA
C14H19Cl2NO2
CAS-305-03-3
CB 1348
Cb l348
CB1348
CB-1348
CCRIS 126
CHEBI:28830
CHEMBL515
Chlocambucil
Chloorambucol
chlorambucil
Chlorambucil
Chlorambucil (USP/INN)
Chlorambucil [INN:BAN]
Chlorambucilum
Chlorambucilum [INN-Latin]
Chloraminophen
Chloraminophene
Chlorbutin
Chlorbutine
Chlorbutinum
Chloroambucil
Chlorobutin
Chlorobutine
CID2708
Clorambucile
Clorambucile [DCIT]
Clorambucilo
Clorambucilo [INN-Spanish]
CPD000058372
D00266
D002699
DB00291
DivK1c_000688
Ecloril
EINECS 206-162-0
Elcoril
Elcorin
EU-0100227
FT-0083565
g-[P-Di(2-chloroethyl)aminophenyl]butyrate
g-[P-Di(2-chloroethyl)aminophenyl]butyric acid
gamma-[P-Di(2-chloroethyl)aminophenyl]butyrate
gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid
gamma-[P-Di(2-chloroethyl)aminophenyl]butyric acid
glaxo Wellcome brand OF chlorambucil
Glaxo Wellcome Brand of Chlorambucil
GlaxoSmithKline brand OF chlorambucil
GlaxoSmithKline Brand of Chlorambucil
HMS1571G20
HMS1920M15
HMS2090M19
HMS2091A22
HMS502C10
HSDB 3026
IDI1_000688
|
KBio1_000688
KBio2_000558
KBio2_003126
KBio2_005694
KBio3_001191
KBioGR_000766
KBioSS_000558
Leuk ersan
Leukeran
LEUKERAN (TN)
Leukeran tablets
Leukeran Tablets
Leukersan
Leukoran
Linfolizin
Linfolysin
Lopac0_000227
Lopac-C-0253
LS-1158
Lympholysin
MLS000028443
MLS001076130
MolPort-000-152-694
N,N-Di-(2-chloroethyl)-P-aminophenylbutyric acid
N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyrate
N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid
N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyric acid
N,N-Di-2-chloroethyl-g-P-aminophenylbutyrate
N,N-Di-2-chloroethyl-g-P-aminophenylbutyric acid
N,N-Di-2-chloroethyl-γ-P-aminophenylbutyrate
N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid
N,N-Di-2-chloroethyl-γ-P-aminophenylbutyric acid
NCGC00015199-01
NCGC00015199-02
NCGC00015199-03
NCGC00015199-07
NCGC00015199-14
NCGC00023250-00
NCGC00023250-03
NCGC00023250-04
NCGC00023250-05
NCGC00023250-06
NCGC00023250-07
NCGC00023250-08
NCGC00023250-09
NCGC00023250-10
NCI60_002639
NCI-C03485
NINDS_000688
NSC 3088
NSC3088
NSC-3088
Pepstatin
Phenylbuttersaeure-lost
Phenylbuttersaeure-lost [German]
Phenylbutyrate nitrogen mustard
Phenylbutyric acid nitrogen mustard
Phenylbutyric Acid Nitrogen Mustard
Prestwick0_001079
Prestwick1_001079
Prestwick2_001079
Prestwick3_001079
RCRA waste no. U035
Rcra waste number U035
SAM002564202
SMR000058372
SPBio_000249
SPBio_002999
Spectrum_000118
SPECTRUM1500171
Spectrum2_000065
Spectrum3_000336
Spectrum4_000273
Spectrum5_000677
ST50410766
TL8002353
UNII-18D0SL7309
Wellcome brand OF chlorambucil
Wellcome Brand of Chlorambucil
WLN: QV3R DN2G2G
γ-[P-di(2-chloroethyl)aminophenyl]butyrate
γ-[p-di(2-chloroethyl)aminophenyl]butyric acid
γ-[P-di(2-chloroethyl)aminophenyl]butyric acid
|
|
8 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-chloro-a,a-Diphenylbenzyl)imidazole
1-(O-chloro-alpha,alpha-Diphenylbenzyl)imidazole
1-(o-Chlorotrityl)imidazole
1-(O-Chlorotrityl)imidazole
1-(o-Chloro-α,α-diphenylbenzyl)imidazole
1-(O-chloro-α,α-diphenylbenzyl)imidazole
1-(α-(2-chlorophenyl)benzhydryl)imidazole
1-(α-(2-Chlorophenyl)benzhydryl)imidazole
117829-71-7
23593-75-1
33894_FLUKA
33894_RIEDEL
3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591
AB00051951
AC1L1EIW
AC-279
B 5097
BAY 5097
Bay b 5097
BAY b 5097
Bay b 9057
BAY b5097
BAY-5097
Bay-B 5097
BAYb 5097
Bayer brand 1 OF clotrimazole
Bayer Brand 1 of Clotrimazole
Bayer brand 2 OF clotrimazole
Bayer Brand 2 of Clotrimazole
BIDD:GT0450
BIDD:PXR0036
Bio-0442
BPBio1_000126
BRN 0622318
BSPBio_000114
BSPBio_002057
C 6019
C06922
C22H17ClN2
C6019_SIGMA
Canesten
Canesten 1-day cream combi-pak
Canesten 1-Day Cream Combi-Pak
Canesten 1-day therapy
Canesten 1-Day Therapy
Canesten 3-day therapy
Canesten 3-Day Therapy
Canesten 6-day therapy
Canesten 6-Day Therapy
Canesten combi-pak 1-day therapy
Canesten Combi-Pak 1-Day Therapy
Canesten combi-pak 3-day therapy
Canesten Combi-Pak 3-Day Therapy
Canesten cream
Canesten Cream
Canesten solution
Canesten Solution
Canestene
Canestine
Canifug
CAS-23593-75-1
CCRIS 6245
CHEBI:3764
CHEMBL104
Chlotrimazole
CID2812
Cimitidine
Clomatin
Clotrimaderm
Clotrimaderm cream
Clotrimazol
Clotrimazol [INN-Spanish]
clotrimazole
Clotrimazole
Clotrimazole (JP15/USP/INN)
Clotrimazole [USAN:INN:BAN:JAN]
Clotrimazole schering brand
Clotrimazole Schering Brand
Clotrimazolum
Clotrimazolum [INN-Latin]
clotrimeizol
CPD000058306
CPD-8926
Cutistad
D00282
D003022
DB00257
Desamix F
DivK1c_000665
DRG-0072
EINECS 245-764-8
Empecid
Esparol
EU-0100315
FB 5097
FB b 5097
Fem care
Fem Care
FemCare
Gino-Lotremine
Gyne lotrimin
Gyne-lotrimin
Gyne-Lotrimin
Gyne-lotrimin 3
Gyne-Lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-Lotrimin 3 Combination Pack
Gyne-lotrimin combination pack
Gyne-Lotrimin Combination Pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
Gynix
HMS1568F16
HMS1920O21
HMS2051E11
HMS2091G10
HMS502B07
HSDB 3266
I01-3474
IDI1_000665
|
Kanesten
KBio1_000665
KBio2_001823
KBio2_004391
KBio2_006959
KBio3_001277
KBioGR_000850
KBioSS_001823
Klotrimazole
Lopac0_000315
Lopac-C-6019
Lotrimax
Lotrimin
Lotrimin (TN)
Lotrimin af
Lotrimin Af
Lotrimin af cream
Lotrimin AF Cream
Lotrimin af jock-itch cream
Lotrimin AF Jock-Itch Cream
Lotrimin af lotion
Lotrimin AF Lotion
Lotrimin af solution
Lotrimin AF Solution
Lotrimin cream
Lotrimin Cream
Lotrimin lotion
Lotrimin Lotion
Lotrimin solution
Lotrimin Solution
Lotrisone
LS-78271
MLS000028502
MLS000758243
MLS001423972
MolPort-002-557-756
mono-Baycuten
Monobaycuten
Mono-baycuten
Mycelax
Mycelex
Mycelex (TN)
Mycelex 7
Mycelex cream
Mycelex Cream
Mycelex g
Mycelex G
Mycelex otc
Mycelex OTC
Mycelex solution
Mycelex Solution
Mycelex troches
Mycelex Troches
Mycelex twin pack
Mycelex Twin Pack
Mycelex: mycosporinrimazole
Mycelex: MycosporinRimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-7 Combination Pack
Mycelex-g
Mycelex-G
myclo Cream
Myclo Cream
myclo Solution
Myclo Solution
myclo Spray solution
Myclo Spray Solution
myclo-Gyne
Myclo-Gyne
Mycofug
Mycosporin
Mykosporin
Nalbix
NCGC00015251-01
NCGC00015251-02
NCGC00015251-03
NCGC00015251-09
NCGC00093761-01
NCGC00093761-02
NCGC00093761-03
NCGC00093761-04
NCGC00093761-05
NCGC00093761-06
nchembio.65-comp9
nchembio790-comp30
NCIMech_000609
neo-Zol cream
Neo-Zol Cream
NINDS_000665
NSC 257473
NSC257473
Otomax
Pan-Fungex
Pedisafe
Prestwick_120
Prestwick0_000267
Prestwick1_000267
Prestwick2_000267
Prestwick3_000267
QTL1_000024
Rimazole
S1606_Selleck
SAM001247056
Schering brand OF clotrimazole
Schering Brand of Clotrimazole
SMR000058306
SPBio_000176
SPBio_002333
Spectrum_001343
SPECTRUM1500200
Spectrum2_000128
Spectrum3_000359
Spectrum4_000295
Spectrum5_000781
Stiemazol
STK700023
Tibatin
Trimysten
Trivagizole 3
UNII-G07GZ97H65
Veltrim
ZINC03807804
|
|
9 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
10 |
|
Melphalan |
Approved |
Phase 2, Phase 3 |
|
148-82-3 |
460612 4053 |
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
Medphalan
|
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
P-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
P-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
11 |
|
Etoposide |
Approved |
Phase 2, Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
12 |
|
Ondansetron |
Approved |
Phase 3 |
|
99614-02-5 |
4595 |
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
99614-01-4 (mono-hydrochloride)
99614-02-5
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
Dihydrate, ondansetron monohydrochloride
GR 38032
GR 38032X
GR38032F
GR-38032F
HMS2090H16
Hydrochloride, ondansetron
I06-0687
I06-1329
L000456
LS-172305
LS-51878
MolPort-001-944-253
|
Monohydrochloride dihydrate, ondansetron
Monohydrochloride, ondansetron
NCI60_022780
Novo-ondansetron
ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride
Ondansetron monohydrochloride
Ondansetron monohydrochloride dihydrate
Ondansetron, (+,-)-isomer
Ondansetron, (+,-)-Isomer
Ondansetron, (R)-isomer
Ondansetron, (S)-isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
Sandoz ondansetron
SN-307
SPBio_002938
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
UNII-4AF302ESOS
Zofran
ZOFRAN IN PLASTIC CONTAINER
Zofran odt
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
|
|
13 |
|
Iron |
Approved, Experimental |
Phase 3 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
14 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
93-14-1 |
3516 |
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
Aresol
Benylin-e
Breonesin
Bronchol
Ether, guaiacol glyceryl
Glycerin ether
Glycerin guaiacolate
glycero-Guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
|
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesina
Guaifenesine
guaiphenesin
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
Humibid
Hustosil
Hytuss
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
P-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
|
|
15 |
|
Carboplatin |
Approved |
Phase 2, Phase 3 |
|
41575-94-4 |
10339178 38904 498142 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
16 |
|
Morphine |
Approved, Investigational |
Phase 3 |
|
57-27-2 |
5288826 |
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
17 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
18 |
|
Dextromethorphan |
Approved |
Phase 3 |
|
125-71-3 |
5360696 5362449 |
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(-)-3-Methoxy-N-methylmorphinan
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
32062-10-5
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
Balminil DM
Balminil DM Children
Bayer select flu relief
Bayer select head & chest cold
Bayer select night time cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
C06947
Calmylin #1
Canfodion
Cerose-DM
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
Chloraseptic DM
CID3008
CID5360696
CID5362449
Contac day & night cold/flu day caplets
Contac jr. non-drowsy formula
Contac nighttime cold medicine
Contac severe cold formula maximum strength
Contac severe cold formula non-drowsy
Coricidin syrup
Cosylan
Cough-X
Creo-Terpin
D03742
DB00514
DEA No. 9210
Delsym
Delsym Cough Formula
delta-Methorphan
Delta-Methorphan
Demorphan
Demorphan hydrobromide
Demorphan Hydrobromide
Demorphine
Destrometerfano
Destrometerfano [Dcit]
Destrometerfano [DCIT]
Dex
Dextromethorfan
Dextromethorfan [Czech]
dextromethorphan
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan [USP:INN:BAN]
Dextromethorphan bromhydrate
Dextromethorphan Bromhydrate
Dextromethorphan bromide
Dextromethorphan Bromide
Dextromethorphan hydrobromide
Dextromethorphan hydrobromide monohydrate
Dextromethorphan hydrobromide oros tablets
Dextromethorphan hydrobromide, (+-)-isomer
Dextromethorphan hydrobromide, monohydrate
Dextromethorphan hydrochloride
Dextromethorphan, (+-)-isomer
Dextromethorphane
Dextrométhorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dexyromethorphan
Diabe-Tuss DM Syrup
Dimacol
Dimetapp DM
DM
d-Methorphan
|
D-methorphan
D-Methorphan
D-Methorphan hydrobromide
D-Methorphan Hydrobromide
Dormetan
Dormethan
Drixoral cough
Drixoral cough & congestion
Drixoral cough & sore throat
DXM
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN pediatric
Hihustan M.
HMS2090C08
Hold
Hold DM
HSDB 3056
Hydrobromide, dextromethorphan
Hydrochloride, dextromethorphan
Koffex DM
Levomethorphan
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [BAN:DCF:INN]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
l-Methorphan
L-Methorphan
Lopac0_000337
Lopac-D-2531
LS-91837
LS-91838
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MLS000758303
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
Naldecon-DX
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Novahistex DM
Novahistine DM
Ornex severe cold formula
Orthoxicol
PediaCare 1
PediaCare cough-cold formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick_686
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Racemethorphan
RACEMETHORPHAN
Robitussin CF
Robitussin cold & cough
Robitussin cough calmers
Robitussin DM
Robitussin maximum strength cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin pediatric cough
Robitussin pediatric cough & cold
Robitussin Pediatric Cough Suppressant
Robitussin pediatric night relief
Romilar
Rondec DM
Ru-tuss expectorant
SPBio_002378
St. joseph cough syrup
Sucrets 4 Hour Cough Suppressant
Sudafed cough syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-organidin
Tussi-organidin DM NR
Tussi-organidin DM-S NR
Tylenol cold and flu multi-symptom
Tylenol cold and flu no drowsiness
Tylenol cold no drowsiness
Tylenol cough + decongestant liquid
Tylenol cough liquid
Tylenol flu no drowsiness gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
viro-Med
δ-methorphan
|
|
19 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3 |
|
11096-26-7, 209810-58-2 |
|
Synonyms:
Darbepoetin
Darbepoetin alfa,recombinant
|
|
|
20 |
|
Caspofungin |
Approved |
Phase 3 |
|
162808-62-0, 179463-17-3 |
2826718 468682 |
Synonyms:
(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
[1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate
1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
162808-62-0
AC1L45LR
AC1LAHR5
AC1MCVUN
AR-1K4318
Cancidas
Cancidas (TM)
Cancidas (TN)
Capsofungin
CASPO
Caspofungin
Caspofungin (INN)
Caspofungin [INN]
Caspofungin acetate
Caspofungin MSD
Caspofungina
|
CHEBI:474180
CHEMBL374999
CHEMBL499808
CID151068
CID2826718
CID468682
D07626
DB00520
HSDB 7476
L-743,872
LS-186994
LS-187303
LS-187635
M991
MK-0991
n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
nchembio.184-comp7
Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
UNII-F0XDI6ZL63
|
|
21 |
|
Tazobactam |
Approved |
Phase 3 |
|
89786-04-9 |
123630 |
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC1L3X07
AC-7620
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
CID123630
CL298741
|
CL-298741
D00660
DB01606
MolPort-002-500-123
Taszobactam sodium
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
Tazobactamum
YTR 830
YTR 830H
YTR-830
YTR830H
YTR-830H
|
|
22 |
|
Vancomycin |
Approved |
Phase 3 |
|
1404-90-6 |
14969 441141 |
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-b-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-b-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
1404-90-6
1404-93-9 (hydrochloride)
64685-75-2 (sulfate)
Abbott brand OF vancomycin hydrochloride
AB-vancomycin
AC1L24VU
AC1L9AMI
AC1Q29OH
Azupharma brand OF vancomycin hydrochloride
BIDD:GT0353
C06689
C66H75Cl2N9O24
Cell pharm brand OF vancomycin hydrochloride
CHEBI:28001
CHEMBL262777
Chiesi brand OF vancomycin hydrochloride
CID14969
CID441141
CID5311496
CID6426898
CID6917992
combino Brand OF vancomycin hydrochloride
Curasan brand OF vancomycin hydrochloride
D00212
Dakota brand OF vancomycin hydrochloride
DB00512
Diatracin
Dista brand OF vancomycin hydrochloride
EINECS 215-772-6
Eli lilly brand OF vancomycin hydrochloride
Hexal brand OF vancomycin hydrochloride
HSDB 3262
Hydrochloride, vancomycin
Lilly brand OF vancomycin hydrochloride
LMPK14000004
Lopac0_001267
LS-161387
|
MIP brand OF vancomycin hydrochloride
MolPort-001-794-649
NCGC00162383-02
nchembio.350-comp1
Norman brand OF vancomycin hydrochloride
Prestwick0_000497
Prestwick1_000497
Prestwick2_000497
Ratiopharm brand OF vancomycin hydrochloride
SPBio_002314
Sulfate, vancomycin
UNII-6Q205EH1VU
VAN
vanco Azupharma
vanco-Cell
Vancocin
Vancocin (TN)
Vancocin HCL
Vancocine
Vancoled
Vancomicin
Vancomicina
Vancomicina [INN-Spanish]
Vancomicina abbott
Vancomicina chiesi
Vancomicina combino phar
Vancomicina norman
Vancomycin
VANCOMYCIN
Vancomycin (USP)
Vancomycin [USAN:INN:BAN]
Vancomycin HCL
Vancomycin hexal
Vancomycin hydrochloride
Vancomycin lilly
Vancomycin phosphate (1:2)
Vancomycin phosphate (1:2), decahydrate
Vancomycin sulfate
Vancomycine
Vancomycine [INN-French]
Vancomycine dakota
Vancomycin-ratiopharm
Vancomycinum
Vancomycinum [INN-Latin]
Vancor
vanco-Saar
|
|
23 |
|
Piperacillin |
Approved |
Phase 3 |
|
66258-76-2 |
43672 |
Synonyms:
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AB piperacillin
AB-piperacillin
AC1L2ACR
AC1Q5QXJ
AHP brand OF piperacillin sodium
Astrapin brand OF piperacillin sodium
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
Curasan brand OF piperacillin sodium
D08380
EINECS 262-811-8
Fresenius brand OF piperacillin sodium
Hexal brand OF piperacillin sodium
HMS2090H19
Lederle brand OF pipracillin sodium
LS-149794
Monosodium salt, piperacillin
Peperacillin
Peracin
|
Peracin (TN)
PIPC
Pipcil
Pipera hameln
Piperacilina
piperacillin
Piperacillin
Piperacillin (anhydrous)
Piperacillin (INN)
Piperacillin anhydrous
Piperacillin curasan
Piperacillin fresenius
Piperacillin hexal
Piperacillin monosodium salt
Piperacillin Monosodium Salt
Piperacillin ratiopharm
Piperacillin sodium
PIPERACILLIN SODIUM
Piperacillina
Pipéracilline
Piperacillin-ratiopharm
Piperacillinum
Pipera-hameln
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
Ratiopharm brand OF piperacillin sodium
Salt, piperacillin monosodium
Sodium, piperacillin
SPBio_002709
T-1220
UNII-9I628532GX
Wyeth brand OF piperacillin sodium
|
|
24 |
|
Amphotericin B |
Approved, Investigational |
Phase 3 |
|
1397-89-3 |
5280965 14956 |
Synonyms:
12633-72-6
1397-89-3
30782-62-8
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
8055-20-7
AB00513832
Abelcet
Abelecet
ABLC
AC1L1CN2
AC1L24V6
AC1L70KF
AC1L73U6
AC1NQXTD
AC1NTQ32
AC1NUQG4
AC1NY9JC
AC1O7GCZ
AC1O8FQV
AC1O8PFK
AI3-26528
Ambap1397-89-3
Ambisome
AmBisome (TN)
Amfotericina b
Amfotericina B
Amfotericina B [INN-Spanish]
amophotericin B
AMPH-b
AMPH-B
Amphocil
Amphocin
Amphomoronal
Ampho-Moronal
Amphortericin b
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
Amphotericin .BETA.
amphotericin b
Amphotericin B
Amphotericin B (JP15/USP/INN)
Amphotericin B [USAN:INN:JAN]
Amphotericin b cholesterol dispersion
Amphotericin B Cholesterol Dispersion
Amphotericin b colloidal dispersion
Amphotericin B Colloidal Dispersion
amphotericin B liposomal
Amphotericin B, Lipid-based
Amphotericin B, Streptomyces sp.
Amphotericin-B
Amphotericine b
Amphotericine B
Amphotéricine B
Amphotericine B [INN-French]
Amphotericinum
Amphotericinum b
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphotherizin
Amphotherizin [German]
Amphozone
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C06573
C47H73NO17
CCRIS 5963
CHEBI:2682
CHEMBL1200646
CHEMBL267345
|
CID10533925
CID10629638
CID10677275
CID14956
CID1972
CID352546
CID354192
CID5280965
CID5386092
CID5458486
CID5771695
CID6604295
CID6708817
CID6713692
CID9919339
D00203
DB00681
DivK1c_007045
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
Halizon
HMS1569A22
HSDB 3008
HSDB 3008 IAB
I06-0257
KBio1_001989
KBio2_000551
KBio2_003119
KBio2_005687
KBioGR_002298
KBioSS_000551
Liposomal amphotericin b
Liposomal amphotericin B
Liposomal Amphotericin B
LMPK06000002
LNS-AmB
LS-187721
LS-93
MLS002702966
MolPort-006-392-260
Mysteclin-F
NCGC00014913
NCGC00090808-01
NCGC00098014-01
NCGC00179595-01
NCI527017
NCI60_004288
NCIStruc1_001042
NCIStruc2_000920
NKTR-024
NS 718
NSC 527017
NSC527017
NSC-527017
Prestwick_721
Prestwick0_000410
Prestwick1_000410
Prestwick2_000410
Prestwick3_000410
SinuNase
SMP1_000302
SMR001566780
SPBio_000715
SPBio_002279
SpecPlus_000949
Spectrum_000111
Spectrum2_000818
Spectrum4_001779
ST50999656
UNII-7XU7A7DROE
|
|
25 |
|
Zanubrutinib |
Approved, Investigational |
Phase 3 |
|
1691249-45-2 |
|
Synonyms:
|
26 |
|
Idelalisib |
Approved |
Phase 3 |
|
870281-82-6 |
|
Synonyms:
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one
5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one
|
|
|
27 |
|
St. John's Wort |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
84082-80-4 |
|
Synonyms:
Common st johnswort flowering top
Common st. john's wort flowering top
Common st. john's wort herb
Common st. johnswort flowering top
Guanyejinsitao
Hyperici herba
Hypericum nachitschevanicum flowering top
Hypericum perforatum flowering top
Hypoxis hemerocallidea root extract
|
Klamath weed flowering top
Klamathweed flowering top
Saint johns wort
St john's wort
St Johns Wort
St. john’s wort
St. johns wort
St. johnswort flowering top
|
|
28 |
|
Ginseng |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
50647-08-0 |
|
Synonyms:
Aralia ginseng root
Asian ginseng root
Chinese ginseng root
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
Korean ginseng root
Ninjin root
|
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
|
|
29 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3 |
|
59763-91-6 |
|
30 |
|
Anesthetics, Dissociative |
|
Phase 3 |
|
|
|
31 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
32 |
|
Antiemetics |
|
Phase 3 |
|
|
|
33 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
34 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
35 |
|
Antifungal Agents |
|
Phase 3 |
|
|
|
36 |
|
Etoposide phosphate |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Hematinics |
|
Phase 3 |
|
|
|
38 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
39 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
40 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
41 |
|
Chlorpheniramine, phenylpropanolamine drug combination |
|
Phase 3 |
|
|
|
42 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
43 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
44 |
|
Analgesics |
|
Phase 3 |
|
|
|
45 |
|
Cola |
|
Phase 3 |
|
|
|
46 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
47 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
48 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
49 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
50 |
|
Epoetin alfa |
|
Phase 3 |
|
113427-24-0 |
|
Interventional clinical trials:
(show top 50)
(show all 507)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China |
Unknown status |
NCT02844322 |
Phase 4 |
Bortezomib;Rituximab |
2 |
Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China |
Unknown status |
NCT02844361 |
Phase 4 |
|
3 |
The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China |
Unknown status |
NCT02844309 |
Phase 4 |
Thalidomide |
4 |
Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor |
Completed |
NCT00003398 |
Phase 4 |
cyclophosphamide;thiotepa |
5 |
A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia |
Recruiting |
NCT04042376 |
Phase 4 |
Ibrutinib |
6 |
A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) |
Unknown status |
NCT00003924 |
Phase 3 |
|
7 |
A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] |
Unknown status |
NCT00445497 |
Phase 3 |
amoxicillin-clavulanate potassium;ciprofloxacin |
8 |
A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients |
Unknown status |
NCT01316744 |
Phase 3 |
ketamine hydrochloride |
9 |
A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes |
Completed |
NCT00608374 |
Phase 3 |
chlorambucil;fludarabine phosphate |
10 |
iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia |
Completed |
NCT02165397 |
Phase 3 |
Ibrutinib;Placebo;Rituximab |
11 |
Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma |
Completed |
NCT00566332 |
Phase 3 |
Chlorambucil;Fludarabine |
12 |
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. |
Completed |
NCT00801281 |
Phase 3 |
Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2 |
13 |
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial |
Completed |
NCT01231412 |
Phase 3 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus |
14 |
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies |
Completed |
NCT00075478 |
Phase 3 |
Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine |
15 |
A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies |
Completed |
NCT00438958 |
Phase 3 |
|
16 |
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer |
Completed |
NCT00006348 |
Phase 3 |
ondansetron |
17 |
The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial |
Completed |
NCT00003341 |
Phase 3 |
|
18 |
Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
Completed |
NCT00005805 |
Phase 3 |
|
19 |
Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia |
Completed |
NCT00003816 |
Phase 2, Phase 3 |
busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa |
20 |
A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients |
Completed |
NCT00003687 |
Phase 3 |
dextromethorphan hydrobromide;morphine sulfate |
21 |
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy |
Completed |
NCT00070382 |
Phase 3 |
darbepoetin alfa;epoetin alfa |
22 |
The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study |
Completed |
NCT00719563 |
Phase 3 |
American ginseng |
23 |
Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam |
Completed |
NCT00003805 |
Phase 3 |
piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin |
24 |
A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia |
Completed |
NCT00661999 |
Phase 3 |
sodium ferric gluconate complex in sucrose |
25 |
Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) |
Completed |
NCT00750009 |
Phase 3 |
|
26 |
A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials |
Completed |
NCT00003938 |
Phase 3 |
liposomal amphotericin B |
27 |
A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia |
Completed |
NCT00008359 |
Phase 3 |
caspofungin acetate;liposomal amphotericin B |
28 |
Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. |
Completed |
NCT00666211 |
Phase 3 |
|
29 |
A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain |
Completed |
NCT00538850 |
Phase 3 |
Fentanyl sublingual spray;Placebo |
30 |
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers |
Recruiting |
NCT02991638 |
Phase 3 |
Ibrutinib |
31 |
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia |
Active, not recruiting |
NCT01788020 |
Phase 3 |
Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib |
32 |
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) |
Active, not recruiting |
NCT03053440 |
Phase 3 |
BGB-3111;Ibrutinib |
33 |
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study |
Enrolling by invitation |
NCT01804686 |
Phase 3 |
PCI-32765 (Ibrutinib) |
34 |
Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) |
Not yet recruiting |
NCT04263480 |
Phase 3 |
Carfilzomib + Ibrutinib;Ibrutinib |
35 |
Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia |
Not yet recruiting |
NCT04061512 |
Phase 2, Phase 3 |
Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib |
36 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
Terminated |
NCT01732926 |
Phase 3 |
Idelalisib;Rituximab;Bendamustine;Placebo |
37 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
Terminated |
NCT01732913 |
Phase 3 |
Placebo;Rituximab;Idelalisib |
38 |
Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia |
Unknown status |
NCT00041379 |
Phase 1, Phase 2 |
beta alethine |
39 |
Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia |
Unknown status |
NCT02981745 |
Phase 1, Phase 2 |
CT-1530 |
40 |
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 |
Unknown status |
NCT01813227 |
Phase 2 |
Carfilzomib;Rituximab;Dexamethasone |
41 |
Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia |
Unknown status |
NCT02971982 |
Phase 1, Phase 2 |
rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide |
42 |
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network |
Unknown status |
NCT01046006 |
Phase 2 |
Bortezomib, Rituximab, Dexamethasone |
43 |
A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia |
Unknown status |
NCT01142011 |
Phase 2 |
Belimumab |
44 |
Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas |
Unknown status |
NCT00927797 |
Phase 2 |
Cyclophosphamide, Pentostatin, Rituximab |
45 |
Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL |
Unknown status |
NCT01016990 |
Phase 2 |
valproic acid |
46 |
Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies |
Unknown status |
NCT00003163 |
Phase 2 |
cyclophosphamide;melphalan |
47 |
A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy |
Unknown status |
NCT01658241 |
Phase 2 |
panobinostat |
48 |
Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells |
Unknown status |
NCT00397800 |
Phase 1, Phase 2 |
cyclophosphamide;fludarabine phosphate |
49 |
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia |
Completed |
NCT00422656 |
Phase 2 |
Perifosine |
50 |
Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) |
Completed |
NCT00020800 |
Phase 2 |
fludarabine phosphate |
|